Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289741 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
A Phase 4 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT03289741: Completed Phase 4 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03289741 is a Phase 4 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 51 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289741, a Phase 4 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
Primary Outcome
Patients will rate, on a numeric scale of 0 to 10, with 0 being No pain" to 10 being "Worst pain ever" the pain or discomfort experienced with the SSA injection.
Interventions
- BEHAVIORAL Questionnaires
- DRUG Octreotide
- DRUG LAR Lanreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 4 |
What the finished NCT03289741 record still lists
NCT03289741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Questionnaires is the first listed.
NCT03289741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03289741 about?
NCT03289741 is a clinical study titled "A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide". This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
What is the current status of trial NCT03289741?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2017-09-19. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT03289741?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Octreotide (DRUG), LAR Lanreotide (DRUG).
Who is sponsoring clinical trial NCT03289741?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03289741's enrollment target sits among peer trials
51 1249th of 2000 higher than 746 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI